NJ Institute of Technology (NJIT)

- One of only 34 polytechnic universities in the U.S
- State owned university founded in 1881
- 1.74 billion economic impact on NJ
- 130+ degree programs
- More than 11,400 students
- $160+M in research conducted annually
- Earned highest research ranking (R1) from Carnegie
- Ranked #1 nationally for student economic mobility by Forbes
NJ Institute of Innovation (NJII)

- An NJIT-owned 501C3 corporation
- Formed in 2014
- 80+ employees
- $300M+ in revenues since opening its doors
- Headquartered on the NJIT campus
- 4 divisions guide our activities
NJII is a conduit between NJIT and the corporate world – crafting mutually beneficial partnerships that leverage the assets of NJIT.
NJII: a conduit between NJIT and the corporate world

- Diverse Talent
- Research & Technology Development
- Employee Upskilling
- Brand Visibility
- Entrepreneurship & Venture Acceleration
Solution
NJII mapped Romark needs to NJIT capabilities to generate a list of specific development opportunities: a technology & automation roadmap designing the warehouse of the future.

Business Value
“Trusted Third Party” Approach
State-of-the Art Technology Capabilities
Talent Pipeline
Technology & Automation @ Romark Logistics

“We are very excited about our partnership with NJII/NJIT and the impressive team they have assembled. Romark embraces innovation and is consistently researching opportunities for advanced technology throughout the world. By partnering with NJII/NJIT, we gain additional expertise and further expand our R&D capabilities, which will enable us to continue to transform our business and position our clients for the future.”

Marc Lebovitz
President & Owner
Romark Logistics

Press Release:
https://bit.ly/3XMz8Et
Success Story: New Venture Accelerator

Client Need
Expand capability to leverage digital technologies in areas such as target identification, lead discovery, pre-clinical development, and clinical development.

Solution
Merck Digital Science Studio. MDSS supports early-stage biomedical startups with direct investment, access to powerful Azure Cloud computing and opportunities to pilot their technologies in collaboration with discovery and clinical scientists at Merck.

Business Value
Rapid access to state-of-the-art solutions and talent that Merck can shape, potentially acquire, or benefit through equity investment.
“The biopharmaceutical industry has only just started to harness the tremendous opportunity presented by emerging technological developments in AI, and ML. The MDSS will provide a collaborative and entrepreneurial setting where scientists have access to the tools and expertise to fuel important innovations that advance drug discovery and development.”

Fiona Marshall
Senior Vice President - Discovery, Preclinical and Translational Medicine
Merck Research Laboratories.

Thank You

New Jersey Innovation Institute
An NJIT Corporation